Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01219816 | Multi-centric Study(CHEPRALL) | completed | Phase 2 | 57 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04075292 | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 155 | AstraZenecaINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04128501 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting |
| active not recruiting |
| Phase 2 |
| 100 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT04544592 | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | recruiting | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial(UHKT-CAR123-01) | active not recruiting | Early Phase 1 | 18 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07003100 | A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | recruiting | — | 100 | City of Hope Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | enrolling by invitation | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | not yet recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | suspended | — | 60 | Washington University School of MedicineOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)(ZEN-CLL) | not yet recruiting | Phase 2 | 95 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819214 | Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI | not yet recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04972942 | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma(ALLO-T-DART) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05884333 | Cord Blood Transplant in Adults With Blood Cancers | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07061951 | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07328503 | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | not yet recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02910583 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)(Captivate) | completed | Phase 2 | 323 | Pharmacyclics LLC.INDUSTRY | 6 | Sep 10, 2026 | clinicaltrials |
| NCT03104491 | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 44 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04169737 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04940468 | High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology | completed | N/A | 8 | University of Colorado, DenverOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05969002 | Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias | completed | — | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | suspended | Phase 2 | 20 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07813208 | Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival(RWD-Ph+ ALL) | recruiting | — | 500 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | active not recruiting | N/A | 80 | University of West AtticaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05010005 | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | recruiting | Phase 1 | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05326308 | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma(ARIADNE) | recruiting | — | 845 | iOMEDICO AGINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT05557695 | Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom(EPIC) | recruiting | — | 287 | AstraZenecaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05672355 | A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06303687 | VR-PAT and fNIRS to Identify CNS Biomarkers of Pain | not yet recruiting | N/A | 4 | Nationwide Children's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06561360 | A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | recruiting | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | recruiting | Phase 1 | 15 | Paolo Caimi, MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07288515 | Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus(ALICIA(BY)) | recruiting | — | 50 | AstraZenecaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809984 | Prevention of Oral Mucositis in Adults in With Hematologic Malignancy | not yet recruiting | N/A | 206 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01044069 | Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 332 | Hoffmann-La RocheINDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT06539338 | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment(INVISE) | active not recruiting | Phase 1 | 10 | Kite, A Gilead CompanyINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies(Soundtrack-E) | recruiting | Phase 1 / Phase 2 | 408 | AstraZenecaINDUSTRY | 13 | Sep 8, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna KinderkrebsforschungOTHER | 31 | Sep 4, 2026 | clinicaltrials |
| NCT02131584 | Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03824483 | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | active not recruiting | Phase 2 | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04635384 | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test(ACROBAT) | active not recruiting | — | 307 | CareDxINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05140369 | CLL Therapy Approaches in Russia(CLL registry) | active not recruiting | — | 6,000 | AstraZenecaINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials